1. Scrip
  2. >>Business

Biogen's Tecfidera Safe Following IPR Decision – For Now

 
• By Jessica Merrill

Tecfidera accounts for nearly one-third of Biogen's revenues, so the patent decision relieves one overhang for the company. However, other ANDA challenges are ongoing.

SC2002_Baseball_291777503_1200.jpg
Biogen avoided a generic Tecfidera challenge • Source: Shutterstock

The US Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) has ruled in favor of Biogen Inc. in an important inter partes review (IPR) challenge by Mylan NV related to the multiple sclerosis pill Tecfidera (dimethyl fumarate), putting Biogen on more solid financial footing in 2020.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Business